Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.26
- Piotroski Score 4.00
- Grade Buy
- Symbol (KRON)
- Company Kronos Bio, Inc.
- Price $0.87
- Changes Percentage (1.05%)
- Change $0.01
- Day Low $0.85
- Day High $0.92
- Year High $1.60
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.63
- High Stock Price Target $2.25
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.99
- Trailing P/E Ratio -0.37
- Forward P/E Ratio -0.37
- P/E Growth -0.37
- Net Income $-112,673,000
Income Statement
Quarterly
Annual
Latest News of KRON
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kronos mulls 'strategic alternatives' after axing cancer drug development
Kronos Bio has halted the development of istisociclib due to safety concerns from a clinical trial. Facing financial challenges, the company plans to explore strategic options and partnerships for its...
By Yahoo! Finance | 1 week ago -
Eastern Michigan vs. Ohio, Akron vs. Northern Illinois predictions:...
Midweek MACtion features three games with betting picks. Kent State faces a tough challenge against Miami. Northern Illinois is favored against Akron. Ohio aims to continue its dominance against Easte...
By New York Post | 1 week ago -
Saint Mary's (CA) takes on Akron after Marciulionis' 27-point game
Saint Mary's (CA) beat Chattanooga with a strong performance by Augustas Marciulionis. They had a successful season last year with good home record and shooting percentages. Akron had a solid record t...
By AP NEWS | 1 week ago
